Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.46 |
| ▸ | FLT3 | P36888 | 5/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123794 | 1.00 | HRH4 (0.46) | HRH4FLT3NOS1MAPTL3MBTL1 | |
| SCHEMBL1123930 | 0.94 | FLT3 (0.47) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123926 | 0.94 | FLT3 (0.47) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123916 | 0.89 | FLT3 (0.45) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123917 | 0.89 | FLT3 (0.45) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123779 | 0.88 | HTR3E (0.45) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123776 | 0.88 | HTR3E (0.45) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123730 | 0.87 | ENPP1 (0.43) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1123726 | 0.87 | ENPP1 (0.43) | FLT3NOS1MAPTL3MBTL1KDM4E | |
| SCHEMBL1124102 | 0.87 | HRH4 (0.46) | HRH4FLT3MAPTKDM4EHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | claimed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | claimed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | claimed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009123221-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | 全薬工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | CASP3, DPYD, CASP1 | HRH4 3298/4885FLT3 3375/4885NOS1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.